Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Fennec Pharmaceuticals Inc
FENC | US
6.25
USD0.32
5.40%
FENC | US
About Fennec Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
14/04/2026
Close
6.25
Open
5.93
High
6.32
Low
5.93
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park North Carolina.
View LessFENC | US
Risk
96.1
Sharpe
0.37
Luna's Score
52/100
Recommendation
Hold
Luna says (FENC | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
71.6%1 month
96.1%3 months
63.5%6 months
56.5%Returns
Fundamental Ratios
PE
64.86
Fwd. PE
10.62
Price to book
57.93
Debt to equity
-21.93
Debt to assets
0.47
Ent. to EBITDA
17.50
Ent. to rev.
2.36
PEG
-
Other Fundamentals
EBITDA
-13.01M
MarketCap
176.11M
MarketCap(USD)
176.11M
Div. yield
-
Op. margin
-69.39
Erngs. growth
-
Rev. growth
118.40
Ret. on equity
-1.01K
Short ratio
19.88
Short perc.
9.87
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.94
Range1M
2.46
Range3M
3.54
Volumes: Market Activity
Rel. volume
0.76
Price X volume
1.21M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 17.50 | - | Expensive |
| Ent. to Revenue | 2.36 | - | Cheaper |
| PE Ratio | 64.86 | 41.03 | Expensive |
| Price to Book | 57.93 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 63.50 | - | Par |
| Debt to Equity | -21.93 | -1.23 | Cheaper |
| Debt to Assets | 0.47 | 0.25 | Expensive |
| Market Cap | 176.11M | - | Emerging |
